Baricitinib Scores High in Phase III
MedPage Today,
Action Points Note that this trial comparing the JAK inhibitor baricitinib to adalimumab to placebo in rheumatoid arthritis…
Action Points Note that this trial comparing the JAK inhibitor baricitinib to adalimumab to placebo in rheumatoid arthritis…
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and…
Action Points Patients with moderate to severely active rheumatoid arthritis (RA) and inadequate responses to methotrexate (MTX…